

SCIENTIFIC REPORTS

OPEN

Author Correction: Assessment of selected media supplements to improve F/HN lentiviral vector production yields

Jean-François Gélinas¹, Lee A. Davies^{1,2}, Deborah R. Gill^{1,2} & Stephen C. Hyde^{1,2}Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-017-07893-3>, published online 31 August 2017

This Article contains a typographical error.

In the Methods section under subheading ‘Lentiviral vector production’,

“These were transiently transfected with a “transfection mix” of 1.5 µg plasmid DNA per 10⁶ cells using 25 kDa branched polyethylenimine (PEI) (Sigma) at an N:P ratio (ratio of moles of amine groups of cationic polymers to moles of phosphate groups of DNA) of 15:1”

should read:

“These were transiently transfected with a “transfection mix” of 1.5 µg plasmid DNA per 10⁶ cells using 25 kDa branched polyethylenimine (PEI) (Sigma) at an N:P ratio (ratio of moles of amine groups of cationic polymers to moles of phosphate groups of DNA) of 15:1”



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018

¹Gene Medicine Research Group, NDCLS, Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford University, Oxford, UK. ²United Kingdom Cystic Fibrosis Gene Therapy Consortium, Oxford, Edinburgh, London, UK. Correspondence and requests for materials should be addressed to S.C.H. (email: steve.hyde@ndcls.ox.ac.uk)